251 related articles for article (PubMed ID: 30236027)
1. Immunotherapy beyond progression in advanced renal cell carcinoma: a case report and review of the literature.
Rebuzzi SE; Bregni G; Grassi M; Damiani A; Buscaglia M; Buti S; Fornarini G
Immunotherapy; 2018 Sep; 10(13):1123-1132. PubMed ID: 30236027
[TBL] [Abstract][Full Text] [Related]
2. Complete and Prolonged Response of Renal Cell Carcinoma With Rhabdoid Features to Checkpoint Inhibitor Therapy.
Wynja E; Solomon B; Bleeker J
J Immunother; 2018 Sep; 41(7):340-342. PubMed ID: 29965859
[TBL] [Abstract][Full Text] [Related]
3. Emerging immunotherapy in advanced renal cell carcinoma.
Mendiratta P; Rini BI; Ornstein MC
Urol Oncol; 2017 Dec; 35(12):687-693. PubMed ID: 28889919
[TBL] [Abstract][Full Text] [Related]
4. Metastatic Renal Medullary Carcinoma Treated With Immune Checkpoint Inhibitor: Case Report and Literature Review.
Di Stefano RF; Buttigliero C; De Luca E; Reale ML; Pisano C; Leone G; Zichi C; Massa F; Manfredi M; Vignani F; Bollito E; Porpiglia F; Di Maio M; Tucci M
Clin Genitourin Cancer; 2018 Dec; 16(6):e1087-e1090. PubMed ID: 30122516
[No Abstract] [Full Text] [Related]
5. Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer.
Soria F; Beleni AI; D'Andrea D; Resch I; Gust KM; Gontero P; Shariat SF
World J Urol; 2018 Nov; 36(11):1703-1709. PubMed ID: 29549485
[TBL] [Abstract][Full Text] [Related]
6. Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial.
George S; Motzer RJ; Hammers HJ; Redman BG; Kuzel TM; Tykodi SS; Plimack ER; Jiang J; Waxman IM; Rini BI
JAMA Oncol; 2016 Sep; 2(9):1179-86. PubMed ID: 27243803
[TBL] [Abstract][Full Text] [Related]
7. Pseudoprogression: an indicator for cure in combined immunotherapy?
Zhao L; Yang Y; Li W; Li T; Han L; Lin H; Gao Q
Immunotherapy; 2019 Sep; 11(13):1087-1093. PubMed ID: 31361166
[TBL] [Abstract][Full Text] [Related]
8. Pushing the limits of immune-related response: a case of "extreme pseudoprogression".
Wong AS; Thian YL; Kapur J; Leong CN; Kee P; Lee CT; Lee MB
Cancer Immunol Immunother; 2018 Jul; 67(7):1105-1111. PubMed ID: 29728723
[TBL] [Abstract][Full Text] [Related]
9. Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma.
Flippot R; Escudier B; Albiges L
Drugs; 2018 Sep; 78(14):1443-1457. PubMed ID: 30187355
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant therapy in renal cell carcinoma: is resection still solely enough?
Gharib KE
Future Oncol; 2021 Feb; 17(6):633-636. PubMed ID: 33305597
[No Abstract] [Full Text] [Related]
11. Comparison of Radiological Tumor Response Based on iRECIST and RECIST 1.1 in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Programmed Cell Death-1 Inhibitor Therapy.
Zheng B; Shin JH; Li H; Chen Y; Guo Y; Wang M
Korean J Radiol; 2021 Mar; 22(3):366-375. PubMed ID: 33289356
[TBL] [Abstract][Full Text] [Related]
12. Low-Dose Nivolumab in Renal Cell Carcinoma: A Real-World Experience.
Zhao JJ; Kumarakulasinghe NB; Muthu V; Lee M; Walsh R; Low JL; Choo J; Tan HL; Chong WQ; Ang Y; Chan G; Yong WP; Huang Y; Ngoi N; Wong A
Oncology; 2021; 99(3):192-202. PubMed ID: 33440374
[TBL] [Abstract][Full Text] [Related]
13. Treating metastatic clear-cell renal cell carcinoma: beyond immunotherapy.
Perego G; Barzaghi P; Vavassori I; Petrelli F
Med Oncol; 2020 Aug; 37(9):81. PubMed ID: 32767163
[TBL] [Abstract][Full Text] [Related]
14. Serum PD-1 levels measured by ELISA using Nivolumab increased in advanced RCC patients: novel approach to develop companion diagnostics for antibody therapy.
Mizutani K; Horie K; Kato T; Nakane K; Kawakami K; Fujita Y; Ito M
J Cancer Res Clin Oncol; 2019 Jun; 145(6):1661-1663. PubMed ID: 30515569
[No Abstract] [Full Text] [Related]
15. Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers.
Rajan A; Kim C; Heery CR; Guha U; Gulley JL
Hum Vaccin Immunother; 2016 Sep; 12(9):2219-31. PubMed ID: 27135835
[TBL] [Abstract][Full Text] [Related]
16. Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025.
Escudier B; Motzer RJ; Sharma P; Wagstaff J; Plimack ER; Hammers HJ; Donskov F; Gurney H; Sosman JA; Zalewski PG; Harmenberg U; McDermott DF; Choueiri TK; Richardet M; Tomita Y; Ravaud A; Doan J; Zhao H; Hardy H; George S
Eur Urol; 2017 Sep; 72(3):368-376. PubMed ID: 28410865
[TBL] [Abstract][Full Text] [Related]
17. Clinical decision-making for immunotherapy in metastatic renal cell carcinoma.
Schmidinger M
Curr Opin Urol; 2018 Jan; 28(1):29-34. PubMed ID: 29045250
[TBL] [Abstract][Full Text] [Related]
18. The Evaluation of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: Open Challenges in the Clinical Practice.
Raimondi A; Randon G; Sepe P; Claps M; Verzoni E; de Braud F; Procopio G
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31480348
[TBL] [Abstract][Full Text] [Related]
19. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.
Ghatalia P; Zibelman M; Geynisman DM; Plimack ER
Curr Treat Options Oncol; 2017 Jan; 18(1):7. PubMed ID: 28210995
[TBL] [Abstract][Full Text] [Related]
20. [Tumor assessment in immune checkpoint inhibitor therapy : Tumor response, progression and pseudoprogression].
Foller S; Oppel-Heuchel H; Grimm MO
Urologe A; 2018 Nov; 57(11):1316-1325. PubMed ID: 30334063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]